Researchers Conduct Study of Medications to Treat Pediatric and Adolescent Migraine
Study Will Evaluate Rimegepant for Pain Freedom and Other Migraine Symptoms
Researchers at Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center are conducting a study to test the medication Rimegepant for the treatment of migraine headaches in children and adolescents.
The randomized study will evaluate the medication against a placebo, as measured by pain freedom reported in the 2-hour period after the medication is administered. Researchers will also evaluate patients’ reported nausea, sensitivity to light, sensitivity to sound, need for use of rescue medications, and sustained pain freedom for 24 hours.
The medication Rimegepant is currently in use for adults for both acute treatment of migraine and preventive treatment of episodic migraine. Participants eligible for this study are from 6 to 17 years old, with a history of migraine for more than six months.
Study results are expected in early 2023.
Learn more about our advancements in pediatric neurology and neurosurgery.